Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Alzheimer’s disease

Daily naproxen does not stall pre-symptomatic Alzheimer’s in older adults

Researchers say their two-year trial comparing naproxen with placebo has left them with “extreme pessimism regarding any possible role of NSAIDs in Alzheimer’s disease prevention”.

Non-steroidal anti-inflammatory drugs (NSAIDs) are unlikely to prevent Alzheimer’s disease (AD) in people at risk of developing the condition, the authors of a study published in Neurology have concluded (5 April 2019)[1].

Their two-year trial involved 195 people with a family history of AD but no current cognitive disorder. They were randomly assigned to either naproxen sodium 220mg or placebo twice daily and were given a composite pre-symptomatic Alzheimer Progression Score (APS) at baseline, 3-month, 12-month, and 24-month time points based on imaging, cognitive assessment and cerebrospinal fluid biomarker testing.

The researchers found that the pre-symptomatic APS increased significantly in all patients by an average of 0.102 points per year. However, the difference in rate of progression (0.019 points/year) was not statistically significant between the two groups, with people who were taking naproxen experiencing more adverse events.

Observational studies have suggested a link between the use of NSAIDs and reduced AD incidence, but clinical trials demonstrated no efficacy in slowing Alzheimer’s progression in people diagnosed with the disease.

The researchers said this study also suggested no role for NSAIDs in AD prevention in cognitively intact individuals.

“This work has left us with extreme pessimism regarding any possible role of NSAIDs in AD prevention,” they said.

Citation: Clinical Pharmacist DOI: 10.1211/PJ.2019.20206547

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.